A targeted treatment in patients with a specific type of lung cancer is likely to become the new standard of care after trial results showed “a highly clinically meaningful improvement” in outcomes for patients, researchers have said. Results from the LAURA trial of osimertinib (Tagrisso; AstraZeneca) in patients with advanced non-small cell lung cancer, who […]
English (US) ·